Cargando…

Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane

BACKGROUND: Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including photocoagulation and surgery, are being considered as options, but with limited success...

Descripción completa

Detalles Bibliográficos
Autores principales: Godeiro, Katyanne Dantas, de Arantes Frota, Ana Carolina, Antecka, Emilia, Odashiro, Alexandre Nakao, Maloney, Shawn, Fernandes, Bruno, Burnier, Miguel Noel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560378/
https://www.ncbi.nlm.nih.gov/pubmed/16911781
http://dx.doi.org/10.1186/1477-3163-5-21
_version_ 1782129482805542912
author Godeiro, Katyanne Dantas
de Arantes Frota, Ana Carolina
Antecka, Emilia
Odashiro, Alexandre Nakao
Maloney, Shawn
Fernandes, Bruno
Burnier, Miguel Noel
author_facet Godeiro, Katyanne Dantas
de Arantes Frota, Ana Carolina
Antecka, Emilia
Odashiro, Alexandre Nakao
Maloney, Shawn
Fernandes, Bruno
Burnier, Miguel Noel
author_sort Godeiro, Katyanne Dantas
collection PubMed
description BACKGROUND: Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including photocoagulation and surgery, are being considered as options, but with limited success. Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein expressed in benign and malignant prostatic tissues, in some non-prostatic tissues, and in the endothelium of tumor-associated neovasculature of non-prostatic neoplasm. Some studies have suggested that the expression of PSMA is restricted to endothelium from tumor-associated neovasculature and might be stimulated by some tumor-secreted angiogenic factors. However, no previous study demonstrating PSMA expression in non-related tumor neovasculature, such as CNVM, has been performed to date. Furthermore, demonstration of PSMA expression in CNVM in AMD patients could reveal a novel target for antineovascular therapy. The purpose of this study was to evaluate the immunohistochemical expression of PSMA in CNVM from AMD. METHODS: Immunohistochemical analysis, with a standard avidin-biotin complex technique, was performed using an anti-PSMA mouse monoclonal antibody in 30 specimens of surgically excised CNVM from AMD patients. Antibody to an endothelial cell specific marker, factor VIII, was used to confirm the location of the endothelial cells. RESULTS: The angiogenic microvessels of the 30 cases demonstrated negative staining to PSMA while factor VIII was expressed in all cases. Seventy-five percent of the secretory-acinar epithelium of the prostatic hyperplasia specimen stained positive, confirming that the immunohistochemical technique was correctly performed. CONCLUSION: The absence of PSMA expression in non-tumoral neovasculature supports the theory, previously suggested, that endothelial cell PSMA expression may be stimulated by one or more tumor-secreted angiogenic factors. Angiogenesis is very important in neoplasia and the endothelial expression of PSMA in tumor-associated neovasculature may represent a target for antineovasculature-based therapy. The absence of PSMA expression in CNVM suggests that PSMA may not be a potential target for antineovasculature-based therapy.
format Text
id pubmed-1560378
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15603782006-09-07 Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane Godeiro, Katyanne Dantas de Arantes Frota, Ana Carolina Antecka, Emilia Odashiro, Alexandre Nakao Maloney, Shawn Fernandes, Bruno Burnier, Miguel Noel J Carcinog Research BACKGROUND: Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including photocoagulation and surgery, are being considered as options, but with limited success. Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein expressed in benign and malignant prostatic tissues, in some non-prostatic tissues, and in the endothelium of tumor-associated neovasculature of non-prostatic neoplasm. Some studies have suggested that the expression of PSMA is restricted to endothelium from tumor-associated neovasculature and might be stimulated by some tumor-secreted angiogenic factors. However, no previous study demonstrating PSMA expression in non-related tumor neovasculature, such as CNVM, has been performed to date. Furthermore, demonstration of PSMA expression in CNVM in AMD patients could reveal a novel target for antineovascular therapy. The purpose of this study was to evaluate the immunohistochemical expression of PSMA in CNVM from AMD. METHODS: Immunohistochemical analysis, with a standard avidin-biotin complex technique, was performed using an anti-PSMA mouse monoclonal antibody in 30 specimens of surgically excised CNVM from AMD patients. Antibody to an endothelial cell specific marker, factor VIII, was used to confirm the location of the endothelial cells. RESULTS: The angiogenic microvessels of the 30 cases demonstrated negative staining to PSMA while factor VIII was expressed in all cases. Seventy-five percent of the secretory-acinar epithelium of the prostatic hyperplasia specimen stained positive, confirming that the immunohistochemical technique was correctly performed. CONCLUSION: The absence of PSMA expression in non-tumoral neovasculature supports the theory, previously suggested, that endothelial cell PSMA expression may be stimulated by one or more tumor-secreted angiogenic factors. Angiogenesis is very important in neoplasia and the endothelial expression of PSMA in tumor-associated neovasculature may represent a target for antineovasculature-based therapy. The absence of PSMA expression in CNVM suggests that PSMA may not be a potential target for antineovasculature-based therapy. BioMed Central 2006-08-15 /pmc/articles/PMC1560378/ /pubmed/16911781 http://dx.doi.org/10.1186/1477-3163-5-21 Text en Copyright © 2006 Godeiro et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Godeiro, Katyanne Dantas
de Arantes Frota, Ana Carolina
Antecka, Emilia
Odashiro, Alexandre Nakao
Maloney, Shawn
Fernandes, Bruno
Burnier, Miguel Noel
Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title_full Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title_fullStr Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title_full_unstemmed Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title_short Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
title_sort prostate-specific membrane antigen is undetectable in choroidal neovascular membrane
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1560378/
https://www.ncbi.nlm.nih.gov/pubmed/16911781
http://dx.doi.org/10.1186/1477-3163-5-21
work_keys_str_mv AT godeirokatyannedantas prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT dearantesfrotaanacarolina prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT anteckaemilia prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT odashiroalexandrenakao prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT maloneyshawn prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT fernandesbruno prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane
AT burniermiguelnoel prostatespecificmembraneantigenisundetectableinchoroidalneovascularmembrane